ACCESS Newswire

iZafe Group

Share
The First Delivery of Dosell Consumer is Sent to Apoteket AB for Start of Sales

STOCKHOLM, SE / ACCESSWIRE / October 4, 2021 / iZafe Group (STO:IZAFE-B)

iZafe Group AB (publ.) announces that Dosell Consumer will be launched on October 18 via Apoteket AB. The first delivery of Dosell Consumer will be sent to Apoteket today, October 4, before the start of sales. In connection with the launch, the media has been invited to a press conference on October 14, where Dosell Consumer will be presented by, among others, CEO Anders Segerström and by the inventor of Dosell, general practitioner Göran Sjönell.

During the summer, an exclusive collaboration agreement was signed with Apoteket AB to introduce the pharmaceutical robot Dosell on the consumer market in Sweden. iZafe Group creates, together with Apoteket, an opportunity for all 2.3 million people who take medication daily in Sweden to prioritize proactivity to avoid drug injuries or incorrect medication.

"There is no doubt that drug injuries are a real problem in society. It is still difficult to create insight into the subject as, in the first instance in the event of an injury, one cannot point out that it has arisen because of incorrect medication. Every year, about 35,000 elderly people become so ill from their medicines that they must be hospitalized. It is with pride that we make Dosell available to anyone who takes medication regularly and wants to prevent incorrect medication with a better overview of medicines and increased compliance before an injury occurs. When our ongoing issue is completed, we will be able to scale up production and begin the sales period that we have all been patiently waiting for. The upcoming launch to the public is welcomed in a press conference on October 14 where we invited the media." Says Anders Segerström, CEO of iZafe Group.

About Dosell Consumer

Dosell Consumer is a subscription service that will be available for delivery via Apoteket on October 18, 2021. It is already possible to register an interest in securing availability when Dosell Consumer is launched.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafe.se/investor-relations/.

Attachments

The first delivery of Dosell Consumer is sent to Apoteket AB for start of sales

SOURCE: iZafe Group



View source version on accesswire.com:
https://www.accesswire.com/666633/The-First-Delivery-of-Dosell-Consumer-is-Sent-to-Apoteket-AB-for-Start-of-Sales

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release

Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e

Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release

BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut

RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye